Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512278 · ClinicalTrials.gov registry record · Phase 2
Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
A Phase 2 study of Hepatitis C, sponsored by Nizar Zein.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
- 7
- Study locations
NCT00512278: Completed Phase 2 study of Hepatitis C, sponsored by Nizar Zein.
NCT00512278 is a Phase 2 study of Hepatitis C that has completed, run by Nizar Zein. The registered enrollment target is 146 participants, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (92% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00512278, a Phase 2 study of Hepatitis C, has completed, sponsored by Nizar Zein.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
- 7
- Study locations
Study Summary
The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection
Primary Outcome
A comparison of the Proportion of Chronic Hepatitis C Subjects (Treatment Naive,Genotype 1) Who Achieve SVR at Week 72, After 48 Weeks of TreatmentSVR in both study arms
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Infliximab
Study Locations (7)
Ohio
- Case Medical Center - Cleveland
- Cleveland Clinic - Cleveland
Texas
- The Liver Institute at Methodist Dallas - Dallas
- Brooke Army Medical Center - San Antonio
California
- Cedars-Sinai Medical Center, Center for Liver Disease and Transplantation - Los Angeles
Florida
- Advanced Medical Research Center - Port Orange
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT00512278 record still lists
NCT00512278 is an interventional study that assigns participants to a tested intervention. The registered 146 participants enrollment target is mid-sized for trials with a published cap, below the 1,889-participant average among 106 other Hepatitis C trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00512278 lists 7 locations in 5 states (Ohio, Texas, California).
Frequently Asked Questions
What is clinical trial NCT00512278 about?
NCT00512278 is a clinical study titled "Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C". The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection
What is the current status of trial NCT00512278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2007-07. Estimated completion is 2012-05.
What conditions does trial NCT00512278 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00512278?
The interventions under investigation include: Placebo (DRUG), Infliximab (DRUG).
Who is sponsoring clinical trial NCT00512278?
This trial is sponsored by Nizar Zein, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00512278 being conducted?
This trial has 7 study locations across California, Florida, Kentucky, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00512278's enrollment target sits among peer trials
146 47th of 106 higher than 60 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Expanding the Pool in Orthotopic Heart Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients
COMPLETED · Phase 2
-
Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C
COMPLETED · Phase 2
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
COMPLETED · Phase 2
-
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03490929 · 146 participants · Phase 4
CEUS for Blunt Abdominal Trauma in Children
- NCT04755062 · 146 participants · NA
A Culturally-relevant Micronutrient-dense Plant-rich (mNDPR) Dietary Intervention for Native Americans
- NCT04867954 · 146 participants
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
- NCT05051618 · 146 participants · NA
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia